Literature DB >> 14752238

Regulation of plasma hemopexin activity by stimulated endothelial or mesangial cells.

Jola J Kapojos1, Klaas Poelstra, Theo Borghuis, Bernhard Banas, Winston W Bakker.   

Abstract

The pathogenesis of glomerular alterations and proteinuria in corticosteroid-responsive nephrotic syndrome (CRNS) is unknown. As an isoform of plasma hemopexin (Hx) with protease activity may be implicated in this disease, we have studied the inhibition of Hx by ADP and reactivation to its active form by endothelial or mesangial cells in vitro. We hypothesized that these cells might potentially be able to convert the inactivated form of Hx (Hxi) to active Hx (Hxa) in vitro, mediated by cellular ecto-ADPase. Since ecto-ADPase (CD39) is upregulated after stimulation of these cells with lipopolysaccharide (LPS) or certain cytokines, we postulated that this conversion might occur specifically after inflammatory stimulation of these cells. Human endothelial or mesangial cell cultures were incubated overnight with or without LPS (10.0 ng/ml) or TNFalpha (10.0 ng/ml), washed and subsequently incubated with Hxi (1.5 mg/ml) in serum-free conditions (Hxi was prepared by treatment of Hxa with ADP or ADP-beta-S). After 60 min, supernatants were tested for their capacity to alter glomerular extracellular matrix molecules (i.e. ecto-apyrase) in vitro using standard methods, and compared with Hxi that had not been incubated with cells. Supernatants containing Hxa (1.5 mg/ml) served as positive control. The results show significant activity in supernatants with Hxi (prepared using native ADP). However, Hxi inactivated by ADP-beta-S (which is non-hydrolyzable) could not be reactivated after contact with LPS-stimulated or unstimulated cells in vitro. As ecto-ADPase of these cells is upregulated by LPS, we believe that reactivation of Hxi to Hxa is mediated by cellular ecto-ADPase. Although the relevance of this inflammation-mediated activation mechanism of Hx in patients with CRNS requires further experimentation, our preliminary observations suggesting that this mechanism is corticosteroid dependent may support a potential role of Hxa in CRNS. Copyright 2004 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14752238     DOI: 10.1159/000075574

Source DB:  PubMed          Journal:  Nephron Physiol        ISSN: 1660-2137


  7 in total

Review 1.  An alternative view of the proposed alternative activities of hemopexin.

Authors:  Marcia R Mauk; Ann Smith; A Grant Mauk
Journal:  Protein Sci       Date:  2011-03-30       Impact factor: 6.725

2.  Altered activity of plasma hemopexin in patients with minimal change disease in relapse.

Authors:  Winston W Bakker; Catharina M L van Dael; Leonie J W M Pierik; Joanna A E van Wijk; Jeroen Nauta; Theo Borghuis; Jola J Kapojos
Journal:  Pediatr Nephrol       Date:  2005-08-04       Impact factor: 3.714

3.  Hemopexin induces nephrin-dependent reorganization of the actin cytoskeleton in podocytes.

Authors:  Rachel Lennon; Anurag Singh; Gavin I Welsh; Richard J Coward; Simon Satchell; Lan Ni; Peter W Mathieson; Winston W Bakker; Moin A Saleem
Journal:  J Am Soc Nephrol       Date:  2008-08-27       Impact factor: 10.121

4.  Activation of the acute inflammatory phase response in idiopathic nephrotic syndrome: association with clinicopathological phenotypes and with response to corticosteroids.

Authors:  Neus Roca; Cristina Martinez; Elias Jatem; Alvaro Madrid; Mercedes Lopez; Alfons Segarra
Journal:  Clin Kidney J       Date:  2021-03-30

5.  Hemopexin Modulates Expression of Complement Regulatory Proteins in Rat Glomeruli.

Authors:  Maria G Detsika; Elias A Lianos
Journal:  Curr Issues Mol Biol       Date:  2021-09-07       Impact factor: 2.976

Review 6.  Cell biology and genetics of minimal change disease.

Authors:  Moin A Saleem; Yasuko Kobayashi
Journal:  F1000Res       Date:  2016-03-30

7.  Multidimensional inflammatory and immunological endotypes of idiopathic focal segmental glomerulosclerosis and their association with treatment outcomes.

Authors:  Neus Roca; Alvaro Madrid; Mercedes Lopez; Gloria Fraga; Elias Jatem; Jorge Gonzalez; Cristina Martinez; Alfons Segarra
Journal:  Clin Kidney J       Date:  2020-12-14
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.